SLRX vs. TENX, XCUR, ATHA, GOVX, MIRA, BTAI, CYTH, APRE, BFRG, and CARM
Should you be buying Salarius Pharmaceuticals stock or one of its competitors? The main competitors of Salarius Pharmaceuticals include Tenax Therapeutics (TENX), Exicure (XCUR), Athira Pharma (ATHA), GeoVax Labs (GOVX), MIRA Pharmaceuticals (MIRA), BioXcel Therapeutics (BTAI), Cyclo Therapeutics (CYTH), Aprea Therapeutics (APRE), Bullfrog AI (BFRG), and Carisma Therapeutics (CARM). These companies are all part of the "pharmaceutical products" industry.
Salarius Pharmaceuticals vs.
Salarius Pharmaceuticals (NASDAQ:SLRX) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.
Tenax Therapeutics' return on equity of -46.00% beat Salarius Pharmaceuticals' return on equity.
Tenax Therapeutics has a consensus price target of $16.00, suggesting a potential upside of 152.76%. Given Tenax Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tenax Therapeutics is more favorable than Salarius Pharmaceuticals.
11.9% of Salarius Pharmaceuticals shares are held by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are held by institutional investors. 1.4% of Salarius Pharmaceuticals shares are held by company insiders. Comparatively, 3.7% of Tenax Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Salarius Pharmaceuticals has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, Tenax Therapeutics has a beta of 2.14, suggesting that its stock price is 114% more volatile than the S&P 500.
In the previous week, Salarius Pharmaceuticals had 1 more articles in the media than Tenax Therapeutics. MarketBeat recorded 2 mentions for Salarius Pharmaceuticals and 1 mentions for Tenax Therapeutics. Tenax Therapeutics' average media sentiment score of 0.75 beat Salarius Pharmaceuticals' score of 0.02 indicating that Tenax Therapeutics is being referred to more favorably in the news media.
Tenax Therapeutics received 118 more outperform votes than Salarius Pharmaceuticals when rated by MarketBeat users. Likewise, 56.03% of users gave Tenax Therapeutics an outperform vote while only 54.17% of users gave Salarius Pharmaceuticals an outperform vote.
Summary
Tenax Therapeutics beats Salarius Pharmaceuticals on 12 of the 14 factors compared between the two stocks.
Get Salarius Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Salarius Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:SLRX) was last updated on 1/21/2025 by MarketBeat.com Staff
Free SLRX Stock Alerts